サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1793894

組織ベースのゲノム・プロファイリングの世界市場

Tissue-based Genomic Profiling

出版日
ページ情報
英文 386 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.92円
組織ベースのゲノム・プロファイリングの世界市場
出版日: 2025年08月19日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 386 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

組織ベースのゲノム・プロファイリングの世界市場は2030年までに19億米ドルに達する見込み

2024年に14億米ドルと推定される組織ベースのゲノム・プロファイリングの世界市場は、2024年から2030年にかけてCAGR 5.0%で成長し、2030年には19億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるシーケンス技術は、CAGR 5.4%を記録し、分析期間終了までに12億米ドルに達すると予測されます。免疫組織化学分野の成長率は、分析期間中CAGR 3.9％と推定されます。

米国市場は3億8,640万米ドルと推定、中国はCAGR 7.9％で成長予測

米国の組織ベースのゲノム・プロファイリング市場は、2024年には3億8,640万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを7.9%として、2030年までに3億7,690万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.4%と5.0%と予測されています。欧州では、ドイツがCAGR 3.2%で成長すると予測されています。

世界の組織ベースのゲノム・プロファイリング市場- 主要動向と促進要因のまとめ

組織ベースのゲノム・プロファイリングはプレシジョン・オンコロジーの新時代を切り開くか？

組織ベースのゲノム・プロファイリング（TGP）は、ホルマリン固定パラフィン包埋（FFPE）または新鮮組織サンプルの分析を通じて固形腫瘍の遺伝子変化を同定することを可能にし、個別化医療における変革ツールとして登場しました。これにより腫瘍医は、腫瘍に特異的なゲノムの変化に基づいて患者を標的療法や免疫療法に適合させることができ、転帰を改善し、不必要な治療を最小限に抑えることができます。TGPは現在、診断や治療法の選択だけでなく、予後評価や耐性メカニズムのモニタリングにも役立ち、プレシジョン・オンコロジーの中心となっています。

この方法は、特に肺がん、乳がん、大腸がん、前立腺がんなどの臨床腫瘍学診療やがん研究に広く採用されています。次世代シークエンシング（NGS）を用いた単一遺伝子アッセイと包括的パネルの両方に対応しており、がん関連遺伝子全体の数百の変異、増幅、融合が同時に解析されます。臨床ガイドラインがバイオマーカー主導の治療決定を推奨するようになるにつれ、組織ベースのゲノム・プロファイリングはニッチな診断オプションから、治療選択と臨床試験登録のための最前線のツールへと進化しています。

NGSとバイオインフォマティクスの進歩は臨床的有用性をどのように高めているか？

技術の進歩は、TGPの能力と精度を大幅に拡大しています。高スループットのNGSプラットフォームにより、低品質または限られた組織サンプルからでも、高い感度と特異性を備えた超深度シーケンスが可能になりました。ライブラリー調製キット、ハイブリッドキャプチャー技術、PCRベースの濃縮の改善により、以前は検出できなかった希少かつ複雑なバリアントを含め、臨床的に関連する変異のカバレッジが向上しています。また、納期も改善されつつあり、この技術を日常臨床で使用できるようになってきています。

バイオインフォマティクスの並行した進歩は、データ解釈に革命をもたらしています。クラウドベースのパイプライン、AIを駆使したバリアント分類、統合された臨床データベースにより、膨大なゲノムデータの迅速な解析と、病原性や薬剤反応性のアノテーションが可能になりました。これらのツールはまた、ゲノム、トランスクリプトーム、エピジェネティックデータを統合した臨床報告をサポートし、診断精度を高めています。重要なことは、研究室がFFPEサンプルのDNA/RNAの完全性を保持するプロトコルを開発していることです。これらの進歩が相まって、TGPは高精度腫瘍学において信頼できる不可欠な資産となりつつあります。

臨床採用、コンパニオン診断、償還政策はアクセスを拡大できるか？

TGP市場にとって最も強い追い風のひとつは、治療の意思決定経路にゲノムデータが統合されつつあることです。EGFR、ALK、ROS1、BRAF阻害剤などの標的治療薬とともに承認されたコンパニオン診断薬は、現在では多くの場合、適格性を確認するために組織ベースのゲノム確認が必要となります。より多くの抗がん剤がバイオマーカーに依存するようになるにつれて、検証済みの高スループットゲノムプロファイリングプラットフォームに対する需要が高まっています。これと並行して、大学医療センターや主要ながん専門病院では、腫瘍診断や治療計画のルーチンとしてTGPを採用するようになっています。

償還政策も進化しています。多くの国において、公的および民間の支払者は、特にガイドラインが推奨する標的療法と関連する場合、特定のがん種に対する包括的ゲノム・プロファイリングをカバーし始めています。規制機関は、より時間がかかり、費用対効果に劣る逐次的な単一遺伝子検査よりも、マルチプレックス・パネルの臨床的有用性を認識しつつあります。病理検査室へのトレーニングやインフラ投資、診断会社と医療機関との提携により、中堅病院や研究機関でもTGPが利用できるようになってきています。このような努力は、アクセスを民主化し、がん医療における診断の不平等を軽減しています。

組織ベースのゲノム・プロファイリング市場の世界的成長の原動力は？

組織ベースのゲノム・プロファイリング市場の成長は、技術革新、がん診療の変革、規制の進化に起因するいくつかの相互に関連する力によって牽引されています。第一に、高精度でスループットの高いNGSプラットフォームの普及により、ルーチンの生検サンプルから堅牢でスケーラブルなゲノム解析が可能になりつつあります。第二に、バイオマーカー主導の治療選択に対する臨床的信頼の高まりが、腫瘍組織から直接得られる実用的なゲノムデータに対する需要を促進しています。

第三に、FDAやEMAが承認したコンパニオン診断薬や標的治療薬のリストの拡大が、治療へのアクセスを組織ベースのゲノムインサイトに直結させています。第四に、診療報酬の上昇と国家的な精密医療イニシアティブにより、医療費の負担が軽減され、標準的な治療プロトコールに組み込まれつつあります。第五に、組織処理、シーケンス化学、データ解釈ツールの改善により、失敗率が減少し、課題の多いサンプル条件でもプロファイリングが可能になりつつあります。最後に、腫瘍学のインフラと臨床研究に対する世界の投資により、バイオファーマ、診断薬企業、ヘルスケア機関のパートナーシップが促進され、先進国市場と新興国市場の両方でTGPの導入が加速しています。これらの要因が相まって、組織ベースのゲノム・プロファイリングは次世代がん診断薬および治療薬の中核に位置づけられつつあります。

セグメント

技術（シーケンス技術、免疫組織化学、その他の技術）、用途（個別化医療用途、腫瘍診断用途、研究用途）、最終用途（研究機関最終用途、臨床研究機関最終用途、病院・クリニック最終用途、診断研究所最終用途、製薬・バイオテクノロジー企業最終用途、その他最終用途）

調査対象企業の例

  • Agilent Technologies
  • Bio-Rad Laboratories
  • Biocartis
  • Caris Life Sciences
  • F. Hoffmann-La Roche AG
  • Foundation Medicine（Roche）
  • Guardant Health
  • Illumina, Inc.
  • Invitae Corporation
  • LabCorp（Covance）
  • MDxHealth
  • NanoString Technologies
  • Novogene
  • Personalis, Inc.
  • QIAGEN N.V.
  • Roche Diagnostics
  • SOPHiA GENETICS
  • Thermo Fisher Scientific
  • Veracyte, Inc.
  • WuXi NextCODE

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP38213

Global Tissue-based Genomic Profiling Market to Reach US$1.9 Billion by 2030

The global market for Tissue-based Genomic Profiling estimated at US$1.4 Billion in the year 2024, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Sequencing Techniques, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Immunohistochemistry segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$386.4 Million While China is Forecast to Grow at 7.9% CAGR

The Tissue-based Genomic Profiling market in the U.S. is estimated at US$386.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$376.9 Million by the year 2030 trailing a CAGR of 7.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Tissue-Based Genomic Profiling Market - Key Trends & Drivers Summarized

Is Tissue-Based Genomic Profiling Ushering in a New Era of Precision Oncology?

Tissue-based genomic profiling (TGP) has emerged as a transformative tool in personalized medicine, enabling the identification of genetic alterations in solid tumors through the analysis of formalin-fixed paraffin-embedded (FFPE) or fresh tissue samples. It allows oncologists to match patients with targeted therapies and immunotherapies based on tumor-specific genomic alterations, improving outcomes and minimizing unnecessary treatments. TGP is now central to precision oncology, aiding not only in diagnosis and therapy selection but also in prognostic evaluation and monitoring resistance mechanisms.

This method is being widely adopted in clinical oncology practices and cancer research, especially for lung, breast, colorectal, and prostate cancers. It supports both single-gene assays and comprehensive panels using next-generation sequencing (NGS), which simultaneously analyzes hundreds of mutations, amplifications, and fusions across cancer-related genes. As clinical guidelines increasingly endorse biomarker-driven treatment decisions, tissue-based genomic profiling is evolving from a niche diagnostic option to a frontline tool for therapy selection and trial enrollment.

How Are Advancements in NGS and Bioinformatics Enhancing Clinical Utility?

Technological advancements are significantly expanding the capabilities and accuracy of TGP. High-throughput NGS platforms now allow for ultra-deep sequencing with high sensitivity and specificity, even from low-quality or limited tissue samples. Improvements in library preparation kits, hybrid capture techniques, and PCR-based enrichment are enhancing coverage of clinically relevant mutations, including rare and complex variants that were previously undetectable. Turnaround times are also improving, making the technology more viable for routine clinical use.

Parallel progress in bioinformatics is revolutionizing data interpretation. Cloud-based pipelines, AI-powered variant classification, and integrated clinical databases enable rapid analysis of vast genomic data and annotation of pathogenicity and drug response. These tools also support the integration of genomic, transcriptomic, and epigenetic data into unified clinical reports, enhancing diagnostic precision. Importantly, laboratories are developing protocols to preserve DNA/RNA integrity from FFPE samples-critical for retrospective and real-world analyses. Together, these advancements are making TGP a reliable and indispensable asset in precision oncology.

Can Clinical Adoption, Companion Diagnostics, and Reimbursement Policies Expand Access?

One of the strongest tailwinds for the TGP market is the rising integration of genomic data into therapeutic decision-making pathways. Companion diagnostics approved alongside targeted drugs-such as EGFR, ALK, ROS1, and BRAF inhibitors-now often require tissue-based genomic confirmation for eligibility. As more cancer drugs become biomarker-dependent, the demand for validated, high-throughput genomic profiling platforms is increasing. In parallel, academic medical centers and leading oncology hospitals are adopting TGP as a routine part of tumor boards and treatment planning.

Reimbursement policies are also evolving. In many countries, public and private payers are beginning to cover comprehensive genomic profiling for select cancer types, particularly when linked to a guideline-recommended targeted therapy. Regulatory bodies are increasingly recognizing the clinical utility of multiplex panels over sequential single-gene tests, which are more time-consuming and less cost-effective. Training and infrastructure investments in pathology labs, as well as partnerships between diagnostic companies and healthcare providers, are expanding the availability of TGP even in mid-tier hospitals and research institutions. These efforts are democratizing access and reducing diagnostic inequities in cancer care.

What Is Driving the Global Growth of the Tissue-Based Genomic Profiling Market?

The growth in the tissue-based genomic profiling market is driven by several interrelated forces stemming from technological innovation, oncology practice transformation, and regulatory evolution. First, the widespread adoption of NGS platforms with high accuracy and throughput is enabling robust, scalable genomic analysis from routine biopsy samples. Second, increasing clinical reliance on biomarker-driven treatment selection is driving demand for actionable genomic data derived directly from tumor tissue.

Third, the expanding list of FDA- and EMA-approved companion diagnostics and targeted therapies is linking therapeutic access directly to tissue-based genomic insights. Fourth, rising reimbursement support and national precision medicine initiatives are improving affordability and integration into standard care protocols. Fifth, improved tissue processing, sequencing chemistry, and data interpretation tools are reducing failure rates and making profiling viable even in challenging sample conditions. Lastly, global investment in oncology infrastructure and clinical research is fostering partnerships between biopharma, diagnostics firms, and healthcare institutions, accelerating the adoption of TGP in both developed and emerging markets. Together, these drivers are firmly positioning tissue-based genomic profiling at the heart of next-generation cancer diagnostics and therapeutics.

SCOPE OF STUDY:

The report analyzes the Tissue-based Genomic Profiling market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Sequencing Techniques, Immunohistochemistry, Other Technologies); Application (Personalized Medicine Application, Oncological Diagnostics Application, Research Application); End-Use (Research Institutes End-Use, Clinical Research Organizations End-Use, Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Agilent Technologies
  • Bio-Rad Laboratories
  • Biocartis
  • Caris Life Sciences
  • F. Hoffmann-La Roche AG
  • Foundation Medicine (Roche)
  • Guardant Health
  • Illumina, Inc.
  • Invitae Corporation
  • LabCorp (Covance)
  • MDxHealth
  • NanoString Technologies
  • Novogene
  • Personalis, Inc.
  • QIAGEN N.V.
  • Roche Diagnostics
  • SOPHiA GENETICS
  • Thermo Fisher Scientific
  • Veracyte, Inc.
  • WuXi NextCODE

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Tissue-based Genomic Profiling - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Adoption of Precision Oncology Drives Demand for Tissue-Based Genomic Profiling
    • Expansion of Targeted Therapy Approvals Spurs Need for Biomarker-Driven Diagnostics
    • Increased Use of NGS Platforms in Hospital and Academic Labs Enhances Testing Capacity
    • Growing Emphasis on Tumor Heterogeneity Analysis Fuels Multiplexed Genomic Assay Adoption
    • Integration of Genomic Profiling With Clinical Decision Support Tools Improves Treatment Personalization
    • Wider Insurance Coverage for Companion Diagnostics Expands Accessibility in Oncology Care
    • Increased Inclusion of Genomic Testing in Clinical Trials Strengthens Institutional Demand
    • Technological Advancements in FFPE Sample Processing Improve Assay Accuracy
    • Rising Prevalence of Solid Tumors Supports Market Growth in Breast, Lung, and Colorectal Cancer Segments
    • Adoption of Pan-Cancer Genomic Panels Accelerates Standardization in Diagnostic Workflows
    • Growth in Oncology Centers and Molecular Pathology Labs Drives Test Volume Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Tissue-based Genomic Profiling Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Tissue-based Genomic Profiling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Tissue-based Genomic Profiling by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Sequencing Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Sequencing Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Sequencing Techniques by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Immunohistochemistry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Clinical Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Clinical Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Clinical Research Organizations End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Personalized Medicine Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Personalized Medicine Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Personalized Medicine Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Oncological Diagnostics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Oncological Diagnostics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Oncological Diagnostics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Research Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • JAPAN
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • CHINA
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: China 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • EUROPE
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Tissue-based Genomic Profiling by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Tissue-based Genomic Profiling by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • FRANCE
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: France 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • GERMANY
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Tissue-based Genomic Profiling by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Tissue-based Genomic Profiling by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • INDIA
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: India 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Tissue-based Genomic Profiling by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Tissue-based Genomic Profiling by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Tissue-based Genomic Profiling by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Tissue-based Genomic Profiling by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030
  • AFRICA
    • Tissue-based Genomic Profiling Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Tissue-based Genomic Profiling by Technology - Sequencing Techniques, Immunohistochemistry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Tissue-based Genomic Profiling by Technology - Percentage Breakdown of Value Sales for Sequencing Techniques, Immunohistochemistry and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Tissue-based Genomic Profiling by End-Use - Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Tissue-based Genomic Profiling by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Research Institutes End-Use, Clinical Research Organizations End-Use and Hospitals & Clinics End-Use for the Years 2014, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Tissue-based Genomic Profiling by Application - Personalized Medicine Application, Oncological Diagnostics Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Tissue-based Genomic Profiling by Application - Percentage Breakdown of Value Sales for Personalized Medicine Application, Oncological Diagnostics Application and Research Application for the Years 2014, 2025 & 2030

IV. COMPETITION